Vaccine Politics in Flux: A Shot of Reality Amidst the Trump Administration's Mixed Messages The recent FDA approval of Moderna's mFlusiva flu vaccine has sent shockwaves through the medical community, leaving many to wonder if this marks a genuine shift in the administration's stance on vaccines.
The approval is particularly notable given its use of mRNA technology, which could provide more effective and faster responses to emerging strains.
One possible explanation for the administration's willingness to approve mFlusiva lies in the bureaucratic process itself.